2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Renata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.
Renata Ferrarotto, MD, a medical oncologist in the Department of Thoracic Head and Neck Medical Oncology, in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses the mechanism of action of trilaciclib (G1T28) in extensive-stage small cell lung cancer (ES-SCLC).
Trilaciclib is a CDK4/6 inhibitor that has a very short half-life, according to Ferrarotto; it is administered to patients with ES-SCLC prior to receiving chemotherapy.
The agent arrests hematopoietic progenitor cells that are dependent on CDK4/6 for proliferation. By arresting these cells in G1, it is able to reduce chemotherapy-induced myelosuppression; this leads to a preservation of immune cells and can enhance immune response, Ferrarotto concludes.